Different BTK inhibitors such as ibrutinib and acalabrutinib are approved for the treatment of certain B-cell malignancies (e.g., chronic lymphocytic leukemia) [36]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.